Kamada Ltd. KMDA
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About KMDA
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Kamada Ltd. is an Israel-based biopharmaceutical company focused on specialty plasma-derived therapeutics, with operations spanning the development, manufacture, and commercialization of products targeting rare and serious medical conditions. The company primarily operates in the biotechnology and specialty pharmaceuticals industries, with a business model centered on proprietary plasma-derived protein therapeutics, contract manufacturing services, and plasma collection activities. Kamada’s revenue is generated through sales of commercial products, distribution partnerships, technology licensing, and manufacturing agreements. Its flagship commercial product portfolio has historically included therapies for alpha-1 antitrypsin deficiency, rabies post-exposure prophylaxis, and immune globulin products.
The company serves hospitals, specialty clinics, government healthcare systems, and pharmaceutical partners across multiple international markets. Kamada has developed strategic positioning through vertically integrated plasma collection and manufacturing capabilities, long-term distribution collaborations, and expertise in plasma-derived biologics production. Founded in 1990 in Israel, the company evolved from a niche plasma therapeutics developer into a diversified specialty biopharmaceutical organization with both proprietary products and contract development and manufacturing operations. Over time, Kamada expanded its commercial footprint through acquisitions, plasma collection investments, and partnerships with larger pharmaceutical distributors.
Business Operations
Kamada operates through several core business activities, including commercial sales of plasma-derived therapeutics, plasma collection services, and contract manufacturing. The company’s principal operating units include its specialty therapeutics operations and plasma collection business. Key products include Glassia, an intravenous alpha-1 antitrypsin therapy for hereditary emphysema associated with alpha-1 antitrypsin deficiency, along with anti-rabies immune globulin and various immunoglobulin-based products. Kamada also provides contract manufacturing and fill-and-finish services for pharmaceutical partners utilizing its biologics manufacturing infrastructure.
The company maintains operations in both domestic and international markets, with manufacturing facilities in Israel and plasma collection centers in the United States operated through subsidiaries and affiliated entities. Kamada has historically maintained commercial collaborations with large pharmaceutical organizations for product distribution in major markets, including the United States and Europe. Its assets include plasma fractionation capabilities, proprietary purification technologies, and regulated biologics manufacturing infrastructure. The company also controls several plasma collection centers that support raw material supply for immunoglobulin production and broader plasma-derived therapeutics activities.
Strategic Position & Investments
Kamada’s strategic direction has emphasized expansion of its plasma collection network, growth in specialty immunoglobulin therapies, and diversification of revenue streams through partnerships and manufacturing services. The company has invested in increasing plasma collection capacity in the United States to strengthen supply chain control and support long-term biologics production economics. Kamada has also pursued growth through selective acquisitions and operational integration initiatives designed to support vertical integration within the plasma-derived therapeutics sector.
The company has maintained investment focus on specialty biologics and immune-based therapies, including products targeting infectious diseases and rare pulmonary disorders. Notable strategic transactions have included the acquisition and development of plasma collection assets and collaborations related to distribution and commercialization. Kamada has also pursued opportunities in contract manufacturing and pharmaceutical services to leverage existing biologics infrastructure beyond its proprietary product portfolio. Its involvement in plasma-derived therapeutics positions the company within specialized areas of immunology, rare disease treatment, and biologic manufacturing.
Geographic Footprint
Kamada is headquartered in Rehovot, Israel, and maintains a multinational operational footprint spanning North America, Europe, Latin America, Asia-Pacific, and additional international markets through direct sales, distributors, and strategic partnerships. The company’s principal manufacturing activities are centered in Israel, while a significant portion of its plasma collection activities are located in the United States. Commercial product distribution extends across numerous countries through pharmaceutical alliances and regional commercialization agreements.
The company’s strongest commercial presence has historically been concentrated in the United States, Israel, and selected international healthcare markets where specialty plasma-derived therapeutics are approved and reimbursed. Kamada’s plasma collection network and biologics infrastructure provide operational influence within the global plasma therapeutics supply chain. Its international activities include product licensing arrangements, export operations, and collaborations with pharmaceutical companies and healthcare distributors across multiple continents.
Leadership & Governance
Kamada’s leadership structure combines biotechnology, pharmaceutical manufacturing, and global commercialization expertise. The company was co-founded by David Tsur, who played a major role in establishing the organization’s plasma therapeutics focus and long-term strategic development. Management has emphasized operational scalability, plasma supply security, specialty biologics growth, and disciplined financial management as central components of corporate strategy.
Key members of leadership have included:
- Amir London – Chief Executive Officer
- Ronen Turgeman – Chief Financial Officer
- Erez Shalev – Chief Operating Officer
- David Tsur – Founder and Board Member
- Dr. Revital Bar-Or – Senior executive leadership roles in quality and regulatory operations
The company operates under governance standards applicable to publicly traded biotechnology companies listed on Nasdaq and regulated under Israeli corporate law. Leadership strategy has consistently focused on expanding specialty biologics commercialization, strengthening plasma supply infrastructure, and maintaining regulatory compliance across international markets.